The Ministry of Commerce's price index on the Chinese herbal medicines in Chengdu released on January 17 showed that prices of Chinese herbal medicines had stabilized and recovered during the first quarter, which was 1.54 points higher than the end of December 2011, reaching 110.84 points. The CPI data released by the National Bureau of Statistics on the 12th showed that prices of Chinese herbal medicines and proprietary Chinese medicines rose by 9.7% in December 2011, while western medicine prices fell by 0.6% in the current period, and the price of healthcare services only rose by 0.5%.

Long Xingchao, director of the Chinese Medicine Association Information Center of the Chinese Medicine Association, told the China Securities Journal on the 17th that the recent increase in the price of Chinese herbal medicines was mainly driven by the prices of health-care Chinese herbal medicines, and the Chinese New Year market was playing a leading role. According to reports, the recent increase in Cordyceps 8%, Codonopsis prices rose more than 10%. However, as a whole, Chinese herbal medicines prices will be lower than last year in 2012 and are expected to continue to decline.

Cardio-cerebral vascular medicine led the rise

According to data from the Chinese Medicinal Materials Association's Chinese herbal medicine website, on January 17, the cardiovascular and cerebrovascular 20 index was 1992.48 points, up 6.22% month on month, and the tonic 40 index was 2917.44 points, up 1.56% month-on-month. The two categories of medicinal herbs rose the most.

Codonopsis is the most representative, the medicinal herbs have the effects of strengthening immunity, dilating blood vessels, reducing blood pressure, improving microcirculation, and enhancing hematopoietic function. In July 2011, the price of Codonopsis was more than 100 yuan/kg. After the National Development and Reform Commission made drastic adjustment measures in the same month, the price of Codonopsis in different categories dropped to 35-60 yuan/kg in October. The statistics from the Business Society show that, to date, the price of Codonopsis in the Chinese herbal medicine market in Longxi, Gansu, has once again exceeded 70 yuan/kg, which is more than 15% higher than in the third quarter of 2011.

According to data from the Ministry of Health website on the 17th, the number of health management personnel for hypertension and diabetes in the country reached 44.7 million and 11.46 million, respectively, and chronic health care provides room for growth for traditional Chinese medicine products. People in the industry believe that the extension of the market for health care and cardiovascular and cerebrovascular medicines has made the Spring Festival an important driving force for stimulating the consumption of related Chinese medicine health products.

The prices of some Chinese herbal medicines with large demand and wide application have also steadily rebounded during the Spring Festival. China Securities Journal reporter learned from the Banlangen planting base in Daqing, Heilongjiang, that the current price of Banlangen is about 5.6-5.7 yuan/kg, and the price was about 5 yuan/kg at the end of 2011. The relevant person in charge said that Banlangen has detoxification and detoxification. The function of cooling blood and swelling, and can be used for plant beverage production, due to the large demand at the end of the year, and the product price fell to a low point last year, many manufacturers began to suppress the goods and drive up prices.

Chinese medicine companies weakened pressure

Although the price of Chinese herbal medicines rose significantly during the Spring Festival, it appears to the industry that in 2012, the Chinese herbal medicine industry as a whole will fall in the atmosphere. Due to the large expansion of the cultivation of medicinal herbs last year, the price of related Chinese herbal medicines will accelerate down once it enters the harvest stage. .

Since the second half of 2009, the prices of Chinese herbal medicines have risen for three consecutive years, and the prices of some varieties have multiplied several times. In the traditional Chinese medicine circulation basin, it is popular to say that it has been “three years, three years, three years, three years, and then three years.” The industry generally believes that with the increase in supply of medicinal herbs, the return of large-scale medicine prices will be inevitable.

Long Xingchao expects that the domestic Chinese herbal medicine market may become sluggish during the next two years. According to reports, in the next phase, as the inventory runs out, Chinese herbal medicine prices will return to reasonable levels. The cost pressure of Chinese medicine enterprises in 2012 is relatively optimistic.

In addition, the pace of entry of Chinese medicine products into the EU is also expected to accelerate. Luo Yang, director of the Department of Chinese Medicine of the Chinese Medical and Health Products Import and Export Chamber of Commerce, told the China Securities Journal on the 17th that since 2011, Chinese companies have been more active in registering traditional herbal medicines in the EU. Although there is still no successful registration of Chinese medicine companies, Foci Pharmaceuticals The concentrated Angelica Pill has been approved in Sweden. After the Spring Festival, it can determine whether it can be successfully registered in the European Union. In addition, Chinese medicine companies such as Ling Pharmaceutical and Tasly are actively preparing to register. According to reports, at present, the proportion of Chinese medicine exports to the EU is relatively small, the total amount of which is less than US$20 million, and most of them are plant extracts, Chinese herbal medicines, and Chinese medicine health products. If Foci Pharmaceuticals is registered successfully, it will promote the registration of Chinese medicine companies in the EU and accelerate the development of domestic Chinese medicine companies. (Author: Liu Guofeng)